Literature DB >> 17581929

Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV realtime assay [corrected] and VERSANT HCV RNA assay.

Edouard Tuaillon1, Anne-Marie Mondain, Laure Ottomani, Laurent Roudière, Pascal Perney, Marie-Christine Picot, Fabienne Séguret, François Blanc, Dominique Larrey, Philippe Van de Perre, Jacques Ducos.   

Abstract

The VERSANT HCV RNA 3.0 (bDNA), COBAS AmpliPrep/COBAS TaqMan HCV, and Abbott ART HCV RealTime assays were compared for hepatitis C virus RNA quantification in 158 clinical specimens (genotypes 1 to 5). RNA values differed significantly between methods (P < 0.0001), and mean titer differences ranged from 0.01 to 0.50 log(10) IU/ml depending on the genotypes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17581929      PMCID： PMC2045299          DOI： 10.1128/JCM.00111-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.

Authors:  Philippe Halfon; Guillaume Pénaranda; Marc Bourlière; Hacène Khiri; Marie-France Masseyeff; Denis Ouzan
Journal:  J Med Virol       Date:  2006-02       Impact factor: 2.327

Review 2.  HCV virological assessment.

Authors:  Xavier Forns; Josep Costa
Journal:  J Hepatol       Date:  2005-11-22       Impact factor: 25.083

3.  Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

Authors:  Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; Tobias Heintges; Alexandra Bergk; Christine Bernsmeier; Dieter Häussinger; Eva Herrmann; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 4.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Authors:  Peter Simmonds; Jens Bukh; Christophe Combet; Gilbert Deléage; Nobuyuki Enomoto; Stephen Feinstone; Phillippe Halfon; Geneviève Inchauspé; Carla Kuiken; Geert Maertens; Masashi Mizokami; Donald G Murphy; Hiroaki Okamoto; Jean-Michel Pawlotsky; François Penin; Erwin Sablon; Tadasu Shin-I; Lieven J Stuyver; Heinz-Jürgen Thiel; Sergei Viazov; Amy J Weiner; Anders Widell
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

5.  Multilaboratory comparison of hepatitis C virus viral load assays.

Authors:  A M Caliendo; A Valsamakis; Y Zhou; B Yen-Lieberman; J Andersen; S Young; A Ferreira-Gonzalez; G J Tsongalis; R Pyles; J W Bremer; N S Lurain
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.

Authors:  Thomas Berg; Christoph Sarrazin; Eva Herrmann; Holger Hinrichsen; Tilman Gerlach; Reinhart Zachoval; Bertram Wiedenmann; Uwe Hopf; Stefan Zeuzem
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

8.  Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.

Authors:  N A Terrault; J-M Pawlotsky; J McHutchison; F Anderson; M Krajden; S Gordon; I Zitron; R Perrillo; R Gish; M Holodniy; M Friesenhahn
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

9.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.

Authors:  Christoph Sarrazin; Barbara C Gärtner; Dorothea Sizmann; Rainer Babiel; Ulrike Mihm; Wolf Peter Hofmann; Michael von Wagner; Stefan Zeuzem
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948
View more
  6 in total

1.  Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens.

Authors:  Jan Felix Drexler; Ulrike Reber; Andrea Wuttkopf; Anna Maria Eis-Hübinger; Christian Drosten
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes.

Authors:  Heidi LaRue; Lisa Rigali; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

3.  Sequence conservation of the region targeted by the Abbott RealTime HCV viral load assay.

Authors:  Gavin Cloherty; Neil Parkin; James Rhoads; Claudia Esping; Corklin Steinhart; George Schneider; Lily Yuen; John Hackett
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

4.  Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.

Authors:  Johannes Vermehren; Annika Kau; Barbara C Gärtner; Reinhild Göbel; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

5.  Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.

Authors:  Robert Strassl; Karoline Rutter; Albert Friedrich Stättermayer; Sandra Beinhardt; Michael Kammer; Harald Hofer; Peter Ferenci; Theresia Popow-Kraupp
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

6.  A novel diagnostic target in the hepatitis C virus genome.

Authors:  Jan Felix Drexler; Bernd Kupfer; Nadine Petersen; Rejane Maria Tommasini Grotto; Silvia Maria Corvino Rodrigues; Klaus Grywna; Marcus Panning; Augustina Annan; Giovanni Faria Silva; Jill Douglas; Evelyn S C Koay; Heidi Smuts; Eduardo M Netto; Peter Simmonds; Maria Inês de Moura Campos Pardini; W Kurt Roth; Christian Drosten
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.